BeyondSpring (NASDAQ:BYSI) Shares Cross Below Fifty Day Moving Average – Here’s What Happened

BeyondSpring Inc. (NASDAQ:BYSI)’s share price passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.41 and traded as low as $0.73. BeyondSpring shares last traded at $0.7420, with a volume of 33,006 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeyondSpring in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

BeyondSpring Stock Performance

The company has a market cap of $30.51 million, a price-to-earnings ratio of -5.30 and a beta of 0.48. The company’s 50 day moving average price is $1.41 and its 200 day moving average price is $1.50.

BeyondSpring (NASDAQ:BYSI) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.49.

Institutional Trading of BeyondSpring

An institutional investor recently bought a new stake in BeyondSpring stock. State Street Corp purchased a new position in shares of BeyondSpring Inc. (NASDAQ:BYSI) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned approximately 0.57% of BeyondSpring as of its most recent filing with the SEC. 40.29% of the stock is currently owned by hedge funds and other institutional investors.

About BeyondSpring

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.